keyword
MENU ▼
Read by QxMD icon Read
search

CTCL

keyword
https://www.readbyqxmd.com/read/28107479/apoptosis-induction-and-gene-expression-profile-alterations-of-cutaneous-t-cell-lymphoma-cells-following-their-exposure-to-bortezomib-and-methotrexate
#1
Vassiliki Mpakou, Evangelia Papadavid, Frieda Kontsioti, Eugene Konsta, Miriam Vikentiou, Aris Spathis, Sotiris Papageorgiou, Diamantina Vasilatou, Konstantinos Gkontopoulos, Efthimia Mpazani, Petros Karakitsos, Dimitrios Rigopoulos, George Dimitriadis, Vasiliki Pappa
Mycosis fungoides (MF) and its leukemic variant Sézary syndrome (SS) comprise the majority of CTCL, a heterogenous group of non-Hodgkins lymphomas involving the skin. The CTCL's resistance to chemotherapy and the lack of full understanding of their pathogenesis request further investigation. With the view of a more targeted therapy, we evaluated in vitro the effectiveness of bortezomib and methotrexate, as well as their combination in CTCL cell lines, regarding apoptosis induction. Our data are of clinical value and indicate that the bortezomib/methotrexate combinational therapy has an inferior impact on the apoptosis of CTCL compared to monotherapy, with bortezomib presenting as the most efficient treatment option for SS and methotrexate for MF...
2017: PloS One
https://www.readbyqxmd.com/read/28054376/toll-like-receptor-tlr-7-expression-in-mycosis-fungoides-and-psoriasis-a-case-control-study
#2
A M El Tawdy, I M Amin, R M Abdel Hay, A S Hassan, Z S Gad, L A Rashed
BACKGROUND: Toll-like receptors (TLRs) have been implicated in various dermatological diseases. TLR agonists have the capacity to potently activate the innate immune cells of patients with advanced, refractory, cutaneous T-cell lymphoma (CTCL). AIM: To detect TLR7 gene expression in mycosis fungoides (MF) (a neoplastic skin condition) and to compare it with psoriasis (an inflammatory skin condition) in an attempt to clarify the pathogenic role played by TLR7 in both conditions...
January 5, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28035219/the-role-of-polymorphism-of-interleukin-2-10-13-and-tnf-%C3%AE-genes-in-cutaneous-t-cell-lymphoma-pathogenesis
#3
Boguslaw Nedoszytko, Berenika Olszewska, Jadwiga Roszkiewicz, Jolanta Glen, Monika Zabłotna, Hanna Ługowska-Umer, Roman Nowicki, Małgorzata Sokołowska-Wojdyło
INTRODUCTION: As the pathogenesis of cutaneous T-cell lymphomas (CTCL) is not fully understood, inherited gene polymorphisms are considered to play a role in the development of lymphomas. AIM: To investigate whether certain gene polymorphisms might be involved in the development of CTCL. MATERIAL AND METHODS: In the case-control study we compared the frequency of nine selected single nucleotide polymorphisms (SNP) of seven genes (rs1800587/-889 C/T of interleukin (IL)-1α, rs2069762/-330G/T) and rs2069763/+166G/T of IL-2, rs1800925/-1112 C/T of IL-13, rs1800896/-1082 A/G of IL-10, rs4073/-251 A/T of IL-8, rs5370/K198N, rs180054/-1370T/G of endothelin-1 and rs1800629/-308 G/A of TNF-α) in 43 CTCL and Polish cases using the amplification refractory mutation system polymerase chain reaction method...
December 2016: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/28007431/quantifying-in-vivo-murine-antigen-specific-t-cell-responses-without-requirement-for-prior-knowledge-of-antigen-identity
#4
Nour Kibbi, Enping Hong, Harib Ezaldein, Douglas Hanlon, Tarek Fahmy, Richard Edelson
Extracorporeal Photochemotherapy (ECP) is a widely applied anti-cancer immunotherapy for patients with cutaneous T cell lymphoma (CTCL). By using apoptotic malignant cells as a source of patient-specific tumor antigen, it enables clinically relevant and curative anti-CTCL immunity, with potential efficacy in other tumors. Currentmethods to track patient-specific responses are tedious, and new methods are needed to assess putative global immunity. We developed a clinically practical method to assess antigen-specific T cell activation that does not rely on knowledge of the particular antigen, thereby eliminating the requirement for patient-specific reagents...
November 30, 2016: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/27998183/systemic-therapy-for-cutaneous-t-cell-lymphoma-who-when-what-and-why
#5
Pooja Virmani, Susan H Hwang, Justin G Hastings, Bradley M Haverkos, Becca Kohnken, Alejandro A Gru, Anjali Mishra, Stephanie K Fabbro, Steve M Horwitz, Pierluigi Porcu
CTCL are rare neoplasms. Optimal care requires integrated use of diagnostic and treatment modalities spanning multiple specialties. Current instruments for patient risk stratification and disease measurement across all anatomical compartments are suboptimal. A common treatment dichotomy between early (Dermatology) and advanced stage (Hematology-Oncology) has hindered accrual of long term outcome data. Thus, important facts about natural history, such as frequency and determinants of stage progression, and the impact of specific treatment modalities on these endpoints, are not known...
December 26, 2016: Expert Review of Hematology
https://www.readbyqxmd.com/read/27995419/t-cell-lymphoma-epidemiology-the-known-and-unknown
#6
REVIEW
Anh Phan, Rachel Veldman, Mary Jo Lechowicz
T-cell lymphoma, a collection of subtypes of Non-Hodgkin lymphoma, is a rare malignancy. The low prevalence of this disease has made it challenging to identify subtype-specific risk factors. Potential risk factors could enable us to identify high-risk patients and predict patient outcomes. Here, we report on the current epidemiologic and prognostic factors data associated with the individual subtypes both of peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) found in large cohort and case studies...
December 2016: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/27982549/latest-insights-into-pathogenesis-of-mycosis-fungoides-cutaneous-t-cell-lymphoma
#7
Laura Y McGirt
Cutaneous T-cell lymphoma (CTCL) is a rare but increasing malignancy whose protean manifestations necessarily present in the integument, but can also spread to involve blood, lymph nodes and internal organs. We have developed efficacious and varied therapies to treat early and advanced stage disease, but there are still many who suffer tremendously from this disease. Although the pathogenesis of this cancer remains frustratingly elusive, over the last 200 years we have generated a robust body of evidence that points toward possible singular as well as multifactorial etiologies...
December 16, 2016: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/27968935/cutaneous-lymphoma-kids-are-not-just-little-people
#8
Katalin Ferenczi, Hanspaul S Makkar
Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that predominantly affect older patients. Onset of cutaneous lymphoma in childhood is rare, but it can present as early as the first decade of life. In both adults and children, the diagnosis of cutaneous lymphoma can be challenging because inflammatory dermatoses can mimic CTCL both clinically and histologically. The clinicopathologic manifestations can be similar in adults and younger individuals; however, differences in the prevalence of certain CTCL variants among age groups exist...
November 2016: Clinics in Dermatology
https://www.readbyqxmd.com/read/27935859/histone-deacetylase-inhibitors-inhibit-metastasis-by-restoring-a-tumor-suppressive-microrna-150-in-advanced-cutaneous-t-cell-lymphoma
#9
Fumito Abe, Akihiro Kitadate, Sho Ikeda, Junsuke Yamashita, Hiroki Nakanishi, Naoto Takahashi, Chikara Asaka, Kazuaki Teshima, Tomomitsu Miyagaki, Makoto Sugaya, Hiroyuki Tagawa
Tumor suppressive microRNA (miR)-150 inhibits metastasis by combining with the C-C chemokine receptor 6 (CCR6) "seed sequence" mRNA of the 3'-untranslated region (3'-UTR) in advanced cutaneous T-cell lymphoma (CTCL). Because the histone deacetylase inhibitor (HDACI) vorinostat showed excellent outcomes for treating advanced CTCL, HDACIs may reduce the metastasis of CTCL by targeting miR-150 and/ or CCR6. To examine whether these candidate molecules are essential HDACI targets in advanced CTCL, we used the My-La, HH, and HUT78 CTCL cell lines for functional analysis because we previously demonstrated that their xenografts in NOD/Shi-scid IL-2γnul mice (CTCL mice) induced multiple metastases...
December 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/27929746/exogenous-expression-of-samhd1-inhibits-proliferation-and-induces-apoptosis-in-cutaneous-t-cell-lymphoma-derived-hut78-cells
#10
Karthik M Kodigepalli, Minghua Li, Shan-Lu Liu, Li Wu
Sterile α motif and HD domain-containing protein 1 (SAMHD1) is a mammalian dNTP hydrolase (dNTPase) that regulates intracellular dNTP balance. We have previously reported that SAMHD1 mRNA and protein levels are significantly downregulated in CD4(+) T-cells of patients with cutaneous T-cell lymphoma (CTCL), a disease characterized by infiltration of neoplastic CD4(+) T-lymphocytes into the skin. However, functional significance of SAMHD1 in CTCL development and progression remains unknown. Here we investigate the mechanism by which SAMHD1 induces apoptosis in CTCL-derived CD4(+) T-cells...
December 8, 2016: Cell Cycle
https://www.readbyqxmd.com/read/27893746/mast-cells-are-abundant-in-primary-cutaneous-t-cell-lymphomas-results-from-a-computer-aided-quantitative-immunohistological-study
#11
Johanna Eder, Radu Rogojanu, Waltraud Jerney, Friedrich Erhart, Alexander Dohnal, Melitta Kitzwögerer, Georg Steiner, Julia Moser, Franz Trautinger
BACKGROUND: Mast cells (MC) are bone marrow derived haematopoetic cells playing a crucial role not only in immune response but also in the tumor microenvironment with protumorigenic and antitumorigenic functions. The role of MC in primary cutaneous T-cell lymphomas (CTCL), a heterogeneous group of non-Hodgkin lymphomas with initial presentation in the skin, is largely unknown. OBJECTIVE: To gain more accurate information about presence, number, distribution and state of activation (degranulated vs...
2016: PloS One
https://www.readbyqxmd.com/read/27889686/microrna-181-contributes-to-downregulation-of-samhd1-expression-in-cd4-t-cells-derived-from-s%C3%A3-zary-syndrome-patients
#12
Rebecca Kohnken, Karthik M Kodigepalli, Anjali Mishra, Pierluigi Porcu, Li Wu
Sézary syndrome (SS) is a rare subtype of cutaneous T-cell lymphoma (CTCL) that is characterized by aggressive spread of neoplastic CD4+ T-cells from the skin into the bloodstream with metastasis to visceral organs. The deoxynucleoside triphosphohydrolase SAMHD1 is highly expressed in normal CD4+ T-cells, while its expression is down-regulated in CD4+ T-cells from SS patients. MicroRNA (miR) dysregulation is an important epigenetic mechanism in the pathogenesis and progression of SS. MiR-181 has been shown to inhibit SAMHD1 expression in cell lines and was identified as an important prognostic biomarker in CTCL...
January 2017: Leukemia Research
https://www.readbyqxmd.com/read/27878874/lymphocytes-from-patients-with-cutaneous-t-cell-lymphoma-show-dna-instability-and-reduced-dna-repair-using-the-comet-assay
#13
LETTER
K Thestrup-Pedersen, C Wang
No abstract text is available yet for this article.
November 23, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27836797/fish-panel-for-leukemic-ctcl
#14
Jason Weed, Juliet Gibson, Julia Lewis, Kacie Carlson, Francine Foss, Jaehyuk Choi, Peining Li, Michael Girardi
No abstract text is available yet for this article.
November 8, 2016: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/27821903/proteomic-approaches-to-biomarker-discovery-in-cutaneous-t-cell-lymphoma
#15
REVIEW
Alexandra Ion, Iris Maria Popa, Laura Maria Lucia Papagheorghe, Cristina Lisievici, Mihai Lupu, Vlad Voiculescu, Constantin Caruntu, Daniel Boda
Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans. CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS). While most cases of MF run a mild course over a period of many years, other subtypes of CTCL are very aggressive. The rapidly expanding fields of proteomics and genomics have not only helped increase knowledge concerning the carcinogenesis and tumor biology of CTCL but also led to the discovery of novel markers for targeted therapy...
2016: Disease Markers
https://www.readbyqxmd.com/read/27813438/targeting-histone-deacetylases-in-t-cell-lymphoma
#16
Alison J Moskowitz, Steven M Horwitz
Histone deacetylase inhibitors (HDACi) are epigenetic modifiers with single-agent activity in patients with cutaneous and peripheral T-cell lymphoma (CTCL, PTCL). The mechanisms for this preferential activity remain unclear, and although some would term this as 'class effect,' there are differences in efficacy and safety, likely a result of the varying chemical structures/classes, histone and non-histone targets, potencies, and clinical dosing for each. Three HDACi have single-agent approval in relapsed/refractory TCL in the United States: romidepsin in CTCL and PTCL, vorinostat in CTCL, and belinostat in PTCL...
November 4, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27805921/c-cbl-e3-ubiquitin-ligase-expression-increases-across-the-spectrum-of-benign-and-malignant-t-cell-skin-diseases
#17
Katrin A Salva, Margo J Reeder, Rita Lloyd, Gary S Wood
Prolonged survival of lesional T cells plays a central role in the pathogenesis of T-cell-mediated dermatoses. We have recently shown that the ubiquitin ligase c-CBL is highly expressed in cutaneous T-cell lymphoma (CTCL) and that its knockdown increases activation-induced cell death, a key pathway for T-cell apoptosis. Here, we extend our work on c-CBL expression in malignant T cells to their nonneoplastic counterparts in benign inflammatory dermatoses. Immunohistochemical staining with anti-c-CBL antibody was performed on lesional biopsies from a total of 65 patients with atopic dermatitis, allergic contact dermatitis, pityriasis rosea, psoriasis vulgaris, lichen planus, mycosis fungoides (MF)/Sézary syndrome (SS) as well as on tonsil tissue from 5 individuals and on 5 human CTCL cell lines...
October 31, 2016: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/27766406/cd164-identifies-cd4-t-cells-highly-expressing-genes-associated-with-malignancy-in-s%C3%A3-zary-syndrome-the-s%C3%A3-zary-signature-genes-fcrl3-tox-and-mir-214
#18
Bernice M Benoit, Neha Jariwala, Geraldine O'Connor, Landon K Oetjen, Timothy M Whelan, Adrienne Werth, Andrea B Troxel, Hélène Sicard, Lisa Zhu, Christopher Miller, Junko Takeshita, Daniel W McVicar, Brian S Kim, Alain H Rook, Maria Wysocka
Sézary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), is associated with a significantly shorter life expectancy compared to skin-restricted mycosis fungoides. Early diagnosis of SS is, therefore, key to achieving enhanced therapeutic responses. However, the lack of a biomarker(s) highly specific for malignant CD4(+) T cells in SS patients has been a serious obstacle in making an early diagnosis. We recently demonstrated the high expression of CD164 on CD4(+) T cells from Sézary syndrome patients with a wide range of circulating tumor burdens...
January 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/27743911/small-molecule-inhibitors-of-ataxia-telangiectasia-and-rad3-related-kinase-atr-sensitize-lymphoma-cells-to-uva-radiation
#19
Edyta Biskup, David Gram Naym, Robert Gniadecki
BACKGROUND: Psoralen plus ultraviolet A (PUVA) photochemotherapy is a combination treatment used for inflammatory and neoplastic skin diseases such as mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL). However, 30% of MF patients do not respond sufficiently to PUVA and require more aggressive therapies. OBJECTIVE: The aim of this project was to investigate whether inhibition of Ataxia Telangiectasia and Rad3 related kinase (ATR) may enhance efficacy of phototherapy...
December 2016: Journal of Dermatological Science
https://www.readbyqxmd.com/read/27741338/75-complete-response-and-15-partial-response-to-extracorporeal-photopheresis-combined-with-other-therapies-in-resistant-early-stage-cutaneous-t-cell-lymphoma
#20
Sila Seremet, Sunil Abhyankar, Tiffany J Herd, Daniel Aires
INTRODUCTION: Extracorporeal photopheresis (ECP) has been used for the treatment of advanced stage or treatment refractory cutaneous T-cell lymphoma (CTCL) since 1987, and more recently has also been shown to be of benefit for earlier stage resistant CTCL. Complete response rates in prior studies of ECP in early CTCL have ranged from 0% to 40%. METHODS: We reviewed electronic medical records of all CTCL patients seen in the University of Kansas Cancer Center between June 2007 and May 2011...
October 1, 2016: Journal of Drugs in Dermatology: JDD
keyword
keyword
43981
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"